Peers

Biocon Ltd. shows moderate growth and profitability metrics compared to its peers but lags in efficiency and valuation attractiveness. Companies like Cipla and Dr. Reddy's Laboratories demonstrate superior profitability and valuation metrics, while Biocon's higher PE ratio indicates it may be overvalued relative to its peers.

• • Biocon has a moderate revenue growth of 3.43% YoY but strong 3-year growth of 27.36%.
• • Cipla and Dr. Reddy's Laboratories are standout performers in profitability and valuation metrics.
• • Cipla's low PE ratio (23.73) and high ROE (16.63%) make it a strong value pick.

• • Cipla Ltd.: Lowest PE ratio (23.73) and highest ROA (13.59%), making it attractive for both growth and value.
• • Dr. Reddy's Laboratories Ltd.: Strong profitability with a ROE of 21.76% and a very low PEG ratio (0.19), indicating it is undervalued.
• • Mankind Pharma Ltd.: Highest revenue growth of 18.12% YoY and strong profitability metrics.